[go: up one dir, main page]

NO20002804L - Konjugater som kan anvendes ved behandling av prostatakreft - Google Patents

Konjugater som kan anvendes ved behandling av prostatakreft

Info

Publication number
NO20002804L
NO20002804L NO20002804A NO20002804A NO20002804L NO 20002804 L NO20002804 L NO 20002804L NO 20002804 A NO20002804 A NO 20002804A NO 20002804 A NO20002804 A NO 20002804A NO 20002804 L NO20002804 L NO 20002804L
Authority
NO
Norway
Prior art keywords
conjugates
treatment
prostate cancer
prostate
cancer
Prior art date
Application number
NO20002804A
Other languages
English (en)
Other versions
NO20002804D0 (no
Inventor
Stephen F Brady
Dong-Mei Feng
Victor M Garsky
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9804399.5A external-priority patent/GB9804399D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20002804D0 publication Critical patent/NO20002804D0/no
Publication of NO20002804L publication Critical patent/NO20002804L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20002804A 1997-12-02 2000-05-31 Konjugater som kan anvendes ved behandling av prostatakreft NO20002804L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6711097P 1997-12-02 1997-12-02
GBGB9804399.5A GB9804399D0 (en) 1998-03-02 1998-03-02 Conjugates useful in the treatment of prostate cancer
PCT/US1998/025358 WO1999028345A1 (en) 1997-12-02 1998-11-25 Conjugates useful in the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
NO20002804D0 NO20002804D0 (no) 2000-05-31
NO20002804L true NO20002804L (no) 2000-07-21

Family

ID=26313204

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002804A NO20002804L (no) 1997-12-02 2000-05-31 Konjugater som kan anvendes ved behandling av prostatakreft

Country Status (26)

Country Link
US (2) US20060148718A1 (no)
EP (1) EP1036093A1 (no)
JP (1) JP2001525337A (no)
KR (1) KR100580137B1 (no)
CN (1) CN1181092C (no)
AR (1) AR016427A1 (no)
AU (1) AU744652B2 (no)
BG (1) BG65486B1 (no)
BR (1) BR9815116A (no)
CA (1) CA2311615A1 (no)
DZ (1) DZ2665A1 (no)
EA (1) EA002745B1 (no)
EE (1) EE200000333A (no)
HR (1) HRP20000367A2 (no)
HU (1) HUP0100350A3 (no)
ID (1) ID24735A (no)
IL (1) IL136167A0 (no)
IS (1) IS5502A (no)
NO (1) NO20002804L (no)
NZ (1) NZ504615A (no)
PE (1) PE20000009A1 (no)
PL (1) PL197006B1 (no)
SK (1) SK8282000A3 (no)
TR (1) TR200002260T2 (no)
TW (1) TW577897B (no)
WO (1) WO1999028345A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518000A (ja) * 1998-12-11 2003-06-03 コールター ファーマシューティカル,インコーポレイティド プロドラッグ化合物およびその調製方法
GB9924759D0 (en) * 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
US7842581B2 (en) 2003-03-27 2010-11-30 Samsung Electronics Co., Ltd. Methods of forming metal layers using oxygen gas as a reaction source and methods of fabricating capacitors using such metal layers
EP3388086B1 (en) 2007-08-17 2020-10-07 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2885006B1 (en) * 2012-08-15 2018-08-08 VisEn Medical, Inc. Prostate specific antigen agents and methods of using same for prostate cancer imaging
WO2014074218A1 (en) * 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
KR20150104092A (ko) 2012-11-15 2015-09-14 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
EP2992531B1 (en) 2013-04-30 2019-06-19 Hewlett-Packard Enterprise Development LP Memory access rate
SI4095130T1 (sl) 2013-10-18 2024-05-31 Novartis Ag Označeni zaviralci za prostato specifičnega membranskega antigena (PSMA), njihova uporaba kot kontrastna sredstva in farmacevtska sredstva za zdravljenje raka prostate
AU2014348601A1 (en) 2013-11-14 2016-05-26 Endocyte, Inc. Compounds for positron emission tomography
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
JP2023554520A (ja) 2020-12-22 2023-12-27 コビオレス エヌヴイ テトラペプチド部分を含む化合物
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4719312A (en) * 1978-10-02 1988-01-12 Merck & Co., Inc. Lysosometropic detergent therapeutic agents
US4376765A (en) * 1980-03-31 1983-03-15 Institut International De Pathologie Cellulaire Et Moleculaire Medicaments, their preparation and compositions containing same
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
ATE64396T1 (de) * 1983-04-29 1991-06-15 Omnichem Sa Konjugierte vinblastin-verbindungen und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
WO1997014416A1 (en) * 1995-10-18 1997-04-24 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
WO1998010651A1 (en) * 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser

Also Published As

Publication number Publication date
PL340768A1 (en) 2001-02-26
KR20010032687A (ko) 2001-04-25
US20060148718A1 (en) 2006-07-06
EA200000603A1 (ru) 2000-12-25
AU744652B2 (en) 2002-02-28
HUP0100350A3 (en) 2001-09-28
NO20002804D0 (no) 2000-05-31
US20070021350A1 (en) 2007-01-25
EE200000333A (et) 2001-08-15
SK8282000A3 (en) 2000-11-07
WO1999028345A1 (en) 1999-06-10
CN1284086A (zh) 2001-02-14
AR016427A1 (es) 2001-07-04
IL136167A0 (en) 2001-05-20
HUP0100350A2 (hu) 2001-08-28
CN1181092C (zh) 2004-12-22
CA2311615A1 (en) 1999-06-10
NZ504615A (en) 2003-05-30
AU1612399A (en) 1999-06-16
ID24735A (id) 2000-08-03
EP1036093A1 (en) 2000-09-20
TW577897B (en) 2004-03-01
TR200002260T2 (tr) 2000-12-21
BG65486B1 (bg) 2008-09-30
HRP20000367A2 (en) 2000-12-31
PL197006B1 (pl) 2008-02-29
EA002745B1 (ru) 2002-08-29
IS5502A (is) 2000-05-19
KR100580137B1 (ko) 2006-05-16
BR9815116A (pt) 2000-10-10
JP2001525337A (ja) 2001-12-11
PE20000009A1 (es) 2000-01-27
BG104563A (en) 2001-04-30
DZ2665A1 (fr) 2003-03-22

Similar Documents

Publication Publication Date Title
NO992069D0 (no) Konjugater som kan anvendes ved behandling av prostatakreft
EP0926955A4 (en) Conjugates useful in the treatment of prostate cancer
NO993396L (no) Kinolin- og kinolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi
NO20002804L (no) Konjugater som kan anvendes ved behandling av prostatakreft
NO985652D0 (no) Anvendelse av naaladaseinhibitorer ved behandling av kreft
NO20013554L (no) Antikonvulsive derivater som kan benyttes ved behandling av klusterhodepiner
NO20034166L (no) Molekyl¶re konjugater for anvendelse ved behandling av cancer
IL189132A0 (en) Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer
DE60045720D1 (de) Behandlung von Krebs beim Menschen mit ET743
NO20022245L (no) Onkolyttiske kombinasjoner for behandling av cancer
NO20020358L (no) Anvendelse av etodolac til behandling av kreft
PT984777E (pt) Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
NO20004141D0 (no) Nye substituerte pyridinoarylpiperaziner er anvendelige ved behandling av benign prostatahyperplasi
EG22346A (en) Process for the preparation of conjugates useful in the treatment of prostate cancer
NO20014228L (no) Radioaktiv cisplatin i behandling av cancer
ZA979655B (en) Conjugates useful in the treatment of prostate cancer.
GB9718160D0 (en) Conjugates useful in the treatment of prostate cancer
GB9804399D0 (en) Conjugates useful in the treatment of prostate cancer
GB9815855D0 (en) Conjugates useful in the treatment of prostate cancer
GB9810183D0 (en) Conjugates useful in the treatment of prostate cancer
GB9624170D0 (en) Conjugates useful in the treatment of prostate cancer
SI0942754T1 (en) Conjugates useful in the treatment of prostate cancer
GB9602903D0 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
AU2001237414A1 (en) Cancer treatment and prognosis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application